Publications by authors named "Josep M Llovet"

100Publications

DNA methylation profiling of human hepatocarcinogenesis.

Hepatology 2020 Nov 25. Epub 2020 Nov 25.

Division of Liver Diseases, Liver Cancer Program, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.31659DOI Listing
November 2020

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.

Liver Int 2020 Nov 14. Epub 2020 Nov 14.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14731DOI Listing
November 2020

Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma.

Clin Cancer Res 2020 Sep 1. Epub 2020 Sep 1.

Liver Cancer Translational Research Group, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-1497DOI Listing
September 2020

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.

J Hepatol 2020 Aug 12;73(2):315-327. Epub 2020 Mar 12.

Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Liver Cancer Program, Divisions of Liver Diseases, Pathology Department and RM Transplant Institute, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2020.03.008DOI Listing
August 2020

The oncogenic role of hepatitis delta virus in hepatocellular carcinoma.

JHEP Rep 2019 Aug 16;1(2):120-130. Epub 2019 May 16.

Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhepr.2019.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001537PMC
August 2019

mRECIST for HCC: Performance and novel refinements.

J Hepatol 2020 02;72(2):288-306

Department of Radiology, University of Pisa, Pisa, Italy; Miami Cancer Institute, Miami, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.09.026DOI Listing
February 2020

Milestones in the pathogenesis and management of primary liver cancer.

J Hepatol 2020 02;72(2):209-214

Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Translational Research in Hepatic Oncology Group, Liver Unit, IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.11.006DOI Listing
February 2020

New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma.

Clin Liver Dis (Hoboken) 2019 Aug 2;14(2):56-61. Epub 2019 Sep 2.

Liver Cancer Translational Research Laboratory Institut d'Investigacions Biomèdiques August Pi I Sunyer-Hospital Clinic, Liver Unit, Universitat de Barcelona Barcelona Catalonia Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cld.796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726379PMC
August 2019

Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.

Liver Int 2019 12 11;39(12):2214-2229. Epub 2019 Sep 11.

Massachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14223DOI Listing
December 2019

An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.

Gastroenterology 2019 11 22;157(5):1383-1397.e11. Epub 2019 Jul 22.

Liver Cancer Translational Research Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic, Liver Unit, Universitat de Barcelona, Barcelona, Catalonia, Spain; Mount Sinai Liver Cancer Program, Department of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, USA; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2019.07.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815707PMC
November 2019

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.

J Hepatol 2019 06 31;70(6):1262-1277. Epub 2019 Mar 31.

Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193007
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.01.028DOI Listing
June 2019

Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.

Gastroenterology 2019 05 6;156(6):1731-1741. Epub 2019 Feb 6.

BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2019.01.261DOI Listing
May 2019

Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.

Clin Cancer Res 2019 04 7;25(7):2021-2023. Epub 2019 Jan 7.

Translational Research in Hepatic Oncology, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3778DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445700PMC
April 2019

Molecular therapies and precision medicine for hepatocellular carcinoma.

Nat Rev Clin Oncol 2018 10;15(10):599-616

Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0073-4DOI Listing
October 2018

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.

Oncogene 2018 07 9;37(27):3740-3752. Epub 2018 Apr 9.

Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-018-0206-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035113PMC
July 2018

Negative phase 3 study of Y microspheres versus sorafenib in HCC.

Lancet Oncol 2018 02;19(2):e69

Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30025-1DOI Listing
February 2018

Beta-catenin cleavage enhances transcriptional activation.

Sci Rep 2018 01 12;8(1):671. Epub 2018 Jan 12.

Department of Internal Medicine, Division of Gastroenterology, University of Kentucky, Lexington, KY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-18421-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766502PMC
January 2018

Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.

J Hepatol 2017 12 24;67(6):1222-1231. Epub 2017 Aug 24.

Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Medicine, Department of Pathology, Recanati Miller Transplantation Institute), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2017.08.013DOI Listing
December 2017

Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma.

Nat Rev Gastroenterol Hepatol 2017 10 2;14(10):571-572. Epub 2017 Aug 2.

Mount Sinai Liver Cancer Program, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York 10029, USA; at the Liver Cancer Translational Research Laboratory, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Univesitat de Barcelona, Rosselló 153, Barcelona 08039, Spain; and at the Institució Catalana de Recerca i Estudis Avançats, Passeig de Lluís Companys 23, Barcelona 08010, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrgastro.2017.103DOI Listing
October 2017

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.

Gastroenterology 2017 09 15;153(3):812-826. Epub 2017 Jun 15.

Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Department of Pathology, Recanati Miller Transplantation Institute), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Liver Cancer Translational Research Laboratory, BCLC, Liver Unit, CIBEREHD, IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2017.06.007DOI Listing
September 2017

Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made".

J Hepatol 2017 07 16;67(1):196-197. Epub 2017 Mar 16.

Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain; Liver Cancer Program, Division of Liver Diseases, Ichan School of Medicine at Mount Sinai, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2017.03.004DOI Listing
July 2017

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

J Hepatol 2017 06 26;66(6):1166-1172. Epub 2017 Jan 26.

Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain; Liver Cancer Program, Division of Liver Diseases, Ichan School of Medicine at Mount Sinai, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2017.01.012DOI Listing
June 2017

Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.

J Hepatol 2017 05 23;66(5):952-961. Epub 2017 Jan 23.

Liver Cancer Translational Research Laboratory, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Catalonia, Spain; Mount Sinai Liver Cancer Program, (Divisions of Liver Diseases, Hematology and Medical Oncology, Department of Medicine, Department of Pathology, Recanati Miller Transplantation Institute), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278173001
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2017.01.010DOI Listing
May 2017

Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.

Gastroenterology 2017 03 30;152(4):745-761. Epub 2016 Dec 30.

Mount Sinai Liver Cancer Program, Divisions of Liver Diseases, Hematology, and Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Liver Cancer Translational Research Laboratory, BCLC, Liver Unit, CIBEREHD, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2016.11.048DOI Listing
March 2017

IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.

Gastroenterology 2016 12 7;151(6):1192-1205. Epub 2016 Sep 7.

Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer Group, Liver Unit, IDIBAPS-Hospital Clínic de Barcelona, CIBERehd Universitat de Barcelona, Catalonia, Spain; Liver Cancer Program, Division of Liver Diseases and Pathology Department, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2016.09.001DOI Listing
December 2016

Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC.

Nat Rev Gastroenterol Hepatol 2016 10 1;13(10):561-2. Epub 2016 Sep 1.

Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute and the Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, Madison Avenue 1425, New York, New York 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrgastro.2016.140DOI Listing
October 2016

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

Lancet Oncol 2016 Oct 27;17(10):1386-1395. Epub 2016 Aug 27.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain; School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30297-2DOI Listing
October 2016

Hepatocellular carcinoma.

Nat Rev Dis Primers 2016 04 14;2:16018. Epub 2016 Apr 14.

Mayo Clinic, Mayo College of Medicine, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrdp.2016.18DOI Listing
April 2016

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

J Hepatol 2016 05 22;64(5):1090-1098. Epub 2016 Jan 22.

Barcelona Clínic Liver Cancer (BCLC) Group, Liver Unit, Institut d'Investigacions Biomèdiques, August Pi i Sunyer (IDIBAPS), Hospital Clínic Barcelona, CIBERehd, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2016.01.012DOI Listing
May 2016

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.

Gut 2017 03 11;66(3):530-540. Epub 2015 Dec 11.

Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/gutjnl-2015-309501DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600200PMC
March 2017

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.

Clin Cancer Res 2016 Jan 24;22(2):291-300. Epub 2015 Sep 24.

Liver Cancer Translational Research Laboratory, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Catalonia, Spain. Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3296DOI Listing
January 2016

Molecular markers predicting outcome in hepatocellular carcinoma treated by liver transplantation.

Authors:
Josep M Llovet

Liver Transpl 2015 Nov;21 Suppl 1:S25-6

Liver Cancer Translational Research Laboratory, Barcelona-Clinic Liver Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lt.24313DOI Listing
November 2015

Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation.

J Hepatol 2015 Dec 26;63(6):1368-77. Epub 2015 Jul 26.

Mount Sinai Liver Cancer Program (Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Department of Pathology, Recanati Miller Transplantation Institute, Department of Surgical Oncology), Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Laboratory, Barcelona - Clínic Liver Cancer Group (Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Liver Unit, Hospital Clínic, Universitat de Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2015.07.025DOI Listing
December 2015

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.

Gastroenterology 2015 Oct 20;149(5):1226-1239.e4. Epub 2015 Jun 20.

Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Liver Cancer Translational Research Laboratory, Barcelona-Clínic Liver Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Liver Unit, CIBEREHD, Hospital Clínic, Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00165085150086
Publisher Site
http://dx.doi.org/10.1053/j.gastro.2015.05.061DOI Listing
October 2015

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Nat Rev Clin Oncol 2015 Jul 9;12(7):408-24. Epub 2015 Jun 9.

Department of Medicine, Division of Haematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.103DOI Listing
July 2015

A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.

Gut 2016 10 4;65(10):1754-64. Epub 2015 Jun 4.

Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/gutjnl-2015-309655DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848165PMC
October 2016

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.

Cell Rep 2015 Mar 12;10(10):1692-1707. Epub 2015 Mar 12.

Cancer Center, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA; Center for Regenerative Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA; Department of Medicine, Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.02.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565791PMC
March 2015

DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma.

Hepatology 2015 Jun 18;61(6):1945-56. Epub 2015 Mar 18.

Liver Cancer Research Program, Division of Liver Diseases, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.27732DOI Listing
June 2015

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.

Nat Commun 2015 Jan 22;6:6087. Epub 2015 Jan 22.

1] Barcelona-Clínic Liver Cancer Group (HCC Translational Research Laboratory, Liver Unit, Hepato-biliary Surgery), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona 08036, Spain [2] Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Medicine, Department of Pathology, Recanati Miller Transplantation Institute), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York 10029, USA [3] Institució Catalana de Recerca i Estudis Avançats, Barcelona 08010, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms7087DOI Listing
January 2015

Unique genomic profile of fibrolamellar hepatocellular carcinoma.

Gastroenterology 2015 Apr 31;148(4):806-18.e10. Epub 2014 Dec 31.

HCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group, Liver Unit, Pathology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBERehd, Hospital Clínic, Universitat de Barcelona, Catalonia, Spain; Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Recanati/Miller Transplantation Institute; Department of Pathology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2014.12.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521774PMC
April 2015

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

J Clin Oncol 2015 Feb 29;33(6):559-66. Epub 2014 Dec 29.

Andrew X. Zhu, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Olivier Rosmorduc, Service d'Hépatologie, Hôpital Saint-Antoine, Paris; Marie-Aude Leberre, Bayer HealthCare Pharmaceuticals, Loos, France; T.R. Jeffry Evans, Beatson West of Scotland Cancer Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow; Paul J. Ross, King's College Hospital, London, United Kingdom; Armando Santoro, Humanitas Cancer Center, Milan, Italy; Flair Jose Carrilho, University of São Paulo School of Medicine, São Paulo, Brazil; Jordi Bruix and Josep M. Llovet, Barcelona Clínic Liver Cancer Group, Institut d'Investigacions Biomèdiques, August Pi i Sunyer, Hospital Clínic Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona; Josep M. Llovet, Institució Catalana de Recerca I Estudis Avançats, Catalonia, Spain; Shukui Qin, People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Jiangsu, China; Paul J. Thuluvath, Institute for Digestive Health and Liver Diseases, Mercy Medical Center, Baltimore, MD; Josep M. Llovet, Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York, NY; Markus Jensen, Bayer Vital GmbH, Leverkusen, Germany; Gerold Meinhardt, Bayer HealthCare Pharmaceuticals, Montville, NJ; and Yoon-Koo Kang, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.7746DOI Listing
February 2015

Molecular profiling of liver tumors: classification and clinical translation for decision making.

Semin Liver Dis 2014 Nov 4;34(4):363-75. Epub 2014 Nov 4.

HCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group (BCLC), Liver Unit, Hospital Clínic, IDIBAPS, CIBEREHD, University of Barcelona, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0034-1394137DOI Listing
November 2014

Integration of genomic information in the clinical management of HCC.

Best Pract Res Clin Gastroenterol 2014 Oct 23;28(5):831-42. Epub 2014 Aug 23.

HCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group (BCLC), Liver Unit, IDIBAPS, Hospital Clínic, CIBERehd, University of Barcelona, C/Rosselló 153, 08036 Barcelona, Catalonia, Spain; Mount Sinai Liver Cancer Program, Icahn School of Medicine at Mount Sinai, Mount Sinai School of Medicine, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2014.08.004DOI Listing
October 2014

Liver cancer: time to evolve trial design after everolimus failure.

Authors:
Josep M Llovet

Nat Rev Clin Oncol 2014 Sep 5;11(9):506-7. Epub 2014 Aug 5.

HCC Translational Research Laboratory, BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, University of Barcelona, Institució Catalana de Recerca i Estudis Avançats, Rosselló 153, 08036 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.136DOI Listing
September 2014

TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma.

J Hepatol 2014 Sep 22;61(3):685-7. Epub 2014 May 22.

HCC Translational Research Lab., Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Spain; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai School, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2014.05.028DOI Listing
September 2014

Hepatocellular carcinoma: genome-scale metabolic models for hepatocellular carcinoma.

Nat Rev Gastroenterol Hepatol 2014 Jun 20;11(6):336-7. Epub 2014 May 20.

HCC Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Rosselló 153, 08036 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrgastro.2014.70DOI Listing
June 2014

Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.

Authors:
Josep M Llovet

Cancer Cell 2014 May;25(5):560-2

Mount Sinai Liver Cancer Program, Division of Liver Diseases, ICAHN School of Medicine at Mount Sinai, New York, NY 10029, USA; HCC Translational Research Lab, BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, University of Barcelona. Barcelona 08036, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona 08036, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.04.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071286PMC
May 2014

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

J Hepatol 2014 Jun 27;60(6):1268-89. Epub 2014 Mar 27.

Division of Gastroenterology and Hepatology, Mayo College of Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2014.01.021DOI Listing
June 2014

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Clin Cancer Res 2014 Apr 3;20(8):2072-9. Epub 2014 Mar 3.

Authors' Affiliations: HCC Translational Research Laboratory, Barcelona-Clínic Liver Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Universitat de Barcelona (UB); Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain; and Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Ichan School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0547DOI Listing
April 2014

Reply to X. Qi et al.

J Clin Oncol 2014 Mar 10;32(9):968-9. Epub 2014 Feb 10.

Icahn School of Medicine at Mount Sinai, New York, NY; and Institut d'investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.3033DOI Listing
March 2014

UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

Cancer Cell 2014 Feb 30;25(2):196-209. Epub 2014 Jan 30.

Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Liver Cancer Program/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951208PMC
February 2014

Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.

Nat Rev Clin Oncol 2014 Feb 7;11(2):73-4. Epub 2014 Jan 7.

HCC Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clínic, University of Barcelona and ICREA, Villarroel 170, Barcelona 08036, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2013.243DOI Listing
February 2014

Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.

Gastroenterology 2013 Dec 5;145(6):1424-35.e1-25. Epub 2013 Sep 5.

Cancer Genome Center, Cold Spring Harbor Laboratory, Woodbury, New York; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2013.08.055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892430PMC
December 2013

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

J Clin Oncol 2013 Oct 26;31(28):3509-16. Epub 2013 Aug 26.

Josep M. Llovet and Charissa Chang, Icahn School of Medicine at Mount Sinai, New York, NY; Josep M. Llovet and Jordi Bruix, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) -Hospital Clinic, University of Barcelona, Barcelona, Spain; Thomas Decaens, University of Paris-Est, and Institut National de la Santé et de la Recherche Médicale, Creteil; Jean-Luc Raoul, Institut Paoli Calmette, Marseille; Eveline Boucher, Service d'Oncologie Médicale, Central Eugene Marquis, Rennes; Eric Assenat, Hôpital Saint Eloi, Montpellier; Valerie Boige, Institut Gustave Roussy, Villejuif; Philippe Mathurin, Hôpital Claude Huriez, Lille; Laetitia Fartoux, Hôpital Saint Antoine, Paris; Jean-Frederic Blanc, Saint-Andre Hospital, Bordeaux, France; Masatoshi Kudo, Kinki University School of Medicine, Osaka, Japan; Yoon-Koo Kang, Asan Medical Center; Ho-Yeong Lim, Samsung Medical Center, Seoul; Won-Young Tak, Kyungpook National University Hospital, Daegu; Joong-Won Park, National Cancer Center, Goyang, Republic of Korea; Deng-Yn Lin, Chang Gung Memorial Hospital and Chang Gung University; Yee Chao, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China; Ronnie T. Poon, University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China; Morris Sherman, Toronto General Hospital, Toronto, Ontario, Canada; Richard S. Finn, University of California at Los Angeles, Los Angeles, CA; and Rana Ezzeddine, David Liu, and Ian Walters, Bristol-Myers Squibb, Wallingford, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.3009DOI Listing
October 2013

Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

J Hepatol 2013 Oct 11;59(4):882-4. Epub 2013 May 11.

HCC Translational Research Laboratory, Barcelona-Clínic Liver Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Universitat de Barcelona (UB), Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2013.05.006DOI Listing
October 2013

A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.

Gastroenterology 2013 Jul 6;145(1):176-187. Epub 2013 Apr 6.

Inserm, UMR-674, Génomique Fonctionnelle des Tumeurs Solides, IUH, Paris, France; Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2013.03.051DOI Listing
July 2013

Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis.

Gastroenterology 2013 May 17;144(5):1024-30. Epub 2013 Jan 17.

Mount Sinai Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2013.01.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633736PMC
May 2013

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Gastroenterology 2013 Mar 9;144(3):512-27. Epub 2013 Jan 9.

Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2013.01.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578068PMC
March 2013

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Gastroenterology 2013 Apr 4;144(4):829-40. Epub 2013 Jan 4.

Barcelona-Clínic Liver Cancer Group (HCC Translational Research Laboratory, Liver Unit, Pathology Department), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Liver Unit, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2013.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624083PMC
April 2013

Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma.

Hepatology 2012 Dec;56(6):2416-9

HCC Translational Research Laboratory Barcelona-Clínic Liver Cancer Group Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Liver Unit, Hospital Clínic Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.26124DOI Listing
December 2012

Medical therapies for hepatocellular carcinoma: a critical view of the evidence.

Nat Rev Gastroenterol Hepatol 2013 Jan 13;10(1):34-42. Epub 2012 Nov 13.

Hepatocellular Carcinoma Translational Research Laboratory, Barcelona Clinic Liver Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Liver Unit, Hospital Clínic, Villarroel 170, Barcelona 08036, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrgastro.2012.199DOI Listing
January 2013

HCC Is promoted by bacterial translocation and TLR-4 signaling: a new paradigm for chemoprevention and management.

Hepatology 2012 Nov;56(5):1998-2000

Department of Medicine, Tisch Cancer Institute, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.26080DOI Listing
November 2012

Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

Gastroenterology 2012 Dec 11;143(6):1660-1669.e7. Epub 2012 Sep 11.

HCC Translational Research Laboratory, Barcelona-Clínic Liver Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2012.09.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505826PMC
December 2012

Induction of hepatocellular carcinoma by in vivo gene targeting.

Proc Natl Acad Sci U S A 2012 Jul 25;109(28):11264-9. Epub 2012 Jun 25.

Department of Medicine, University of Washington, Seattle, WA 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1117032109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396480PMC
July 2012

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

J Hepatol 2012 Oct 19;57(4):821-9. Epub 2012 Jun 19.

Barcelona Clínic Liver Cancer Group, Liver Unit, CIBERehd, Institut d'Investigacions Biomèdiques, August Pi i Sunyer, Hospital Clínic Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2012.06.014DOI Listing
October 2012